We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BMG LABTECH

BMG LABTECH is a manufacturer of a wide range of dedicated and multi-mode microplate instruments ranging from single-... read more Featured Products: More products

Download Mobile App




Early Parkinson's Diagnosis Moves Closer with New Protein Test

By LabMedica International staff writers
Posted on 15 Sep 2016
There is currently no definitive test for Parkinson's and the disease is normally diagnosed through assessment of the patient's medical history, a medical examination, and physical and neurological tests, but this can take years.

A novel real-time quaking-induced conversion (RT-QuIC)-based assay has been to detect alpha-synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients.

Scientists at the University of Edinburgh (UK) applied the RT-QuIC test to 20 samples of cerebrospinal fluid (CSF) taken from patients with Parkinson's disease, alongside samples of 15 healthy controls. More...
CSF was drawn from patients by lumbar puncture and samples with visible red color were excluded to avoid blood contamination. A total quantity of 15 mL of CSF was collected in 20 mL polypropylene tubes and samples were stored on ice until centrifuged for 5 min at 1300g at 4 °C to remove cellular components.

Frontal cortex tissue was taken from patients with Alzheimer’s disease (AD), sporadic Creutzfeldt–Jakob disease (sCJD), and diffuses Lewy body dementia (DLB). Real-time quaking induced aggregation for alpha-synuclein were carried out and incubated in a BMG OPTIMA FLUOstar plate reader (BMG LABTECH, Cary, NC, USA) at 30 °C for 120 hours with intermittent shaking cycles: double orbital with one minute shake (200 rpm), 14 minutes rest. Thioflavin (ThT) fluorescence measurements (450 nm excitation and 480 nm emission) were taken every 15 minutes.

The team found the test was able to identify 19 out of 20 of samples with 95% accuracy and 100% specificity. It was also able to detect buildup of the protein in three spinal fluid samples of individuals at high risk for Parkinson's. The team also applied the test to samples of patients with Lewy body dementia. Compared with control samples, the test was able to detect the disease with 92% accuracy and 100% specificity.

Alison J. Green, PhD, the lead investigator said, “We have already used this technique to develop an accurate test for Creutzfeldt Jacob Disease, another neurodegenerative condition. We hope that with further refinement, our approach will help to improve diagnosis for Parkinson’s patients. “We are also interested in whether the test could be used to identify people with Parkinson’s and Lewy body dementia in the early stages of their illness. These people could then be given the opportunity to take part in trials of new medicines that may slow, or stop, the progression of disease.” The study was published on August 28, 2016, in the journal Annals of Clinical and Translational Neurology.

Related Links:
University of Edinburgh
BMG LABTECH

Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.